Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522568 | 0.84 | PARP1 (0.46) | PARP1AURKAHRH3SLC40A1 | |
| SCHEMBL6517410 | 0.81 | ALDH1A1 (0.51) | PARP1AURKA | |
| SCHEMBL6525014 | 0.80 | RAD52 (0.59) | PARP1AURKAHRH3KAT2B | |
| SCHEMBL6533053 | 0.79 | AURKA (0.54) | PARP1AURKASLC40A1 | |
| SCHEMBL6525635 | 0.78 | AURKA (0.56) | PARP1AURKAHRH3 | |
| SCHEMBL6517375 | 0.77 | AURKA (0.51) | PARP1AURKA | |
| SCHEMBL3454371 | 0.76 | AURKA (0.60) | PARP1AURKA | |
| SCHEMBL6521930 | 0.75 | PARP1 (0.52) | PARP1AURKA | |
| SCHEMBL6522266 | 0.75 | AURKA (0.55) | PARP1AURKA | |
| SCHEMBL3454715 | 0.74 | AURKA (0.55) | PARP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | PARP1 1693/4885AURKA 538/4885HRH3 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.